MA55528A - Synthèse acellulaire optimisée d'antigène b de plasmide d'invasion, compositions associées et procédés d'utilisation - Google Patents
Synthèse acellulaire optimisée d'antigène b de plasmide d'invasion, compositions associées et procédés d'utilisationInfo
- Publication number
- MA55528A MA55528A MA055528A MA55528A MA55528A MA 55528 A MA55528 A MA 55528A MA 055528 A MA055528 A MA 055528A MA 55528 A MA55528 A MA 55528A MA 55528 A MA55528 A MA 55528A
- Authority
- MA
- Morocco
- Prior art keywords
- antigen
- compositions
- methods
- invasion plasmid
- optimized acellular
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000009545 invasion Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000013612 plasmid Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828364P | 2019-04-02 | 2019-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55528A true MA55528A (fr) | 2022-02-09 |
Family
ID=70416548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055528A MA55528A (fr) | 2019-04-02 | 2020-03-27 | Synthèse acellulaire optimisée d'antigène b de plasmide d'invasion, compositions associées et procédés d'utilisation |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12280097B2 (fr) |
| EP (1) | EP3946443A1 (fr) |
| JP (1) | JP2022527206A (fr) |
| KR (1) | KR20210146392A (fr) |
| CN (1) | CN114025789A (fr) |
| AU (1) | AU2020253332A1 (fr) |
| BR (1) | BR112021019826A2 (fr) |
| CA (1) | CA3135489A1 (fr) |
| EA (1) | EA202192401A1 (fr) |
| IL (1) | IL286819A (fr) |
| MA (1) | MA55528A (fr) |
| MX (1) | MX2021012120A (fr) |
| PH (1) | PH12021552430A1 (fr) |
| SG (1) | SG11202110803YA (fr) |
| TW (1) | TW202102527A (fr) |
| WO (1) | WO2020205584A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230052958A (ko) | 2020-08-19 | 2023-04-20 | 박사이트, 인코포레이티드 | 운반-단백질 폴리삭카라이드 접합 방법 |
| EP4294452A4 (fr) * | 2021-02-17 | 2025-09-24 | Vaxcyte Inc | Procédés de purification de polysaccharides et conjugués polypeptidiques correspondants |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994028014A2 (fr) | 1993-05-28 | 1994-12-08 | Chiron Corporation | Peptides inhibiteurs de l'activite des recepteurs d'urokinase |
| US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| CN1912106A (zh) * | 2005-08-09 | 2007-02-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种痢疾多价基因工程菌苗及其制备方法 |
| WO2008118118A1 (fr) * | 2007-03-27 | 2008-10-02 | The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research | Invaplex artificiel |
| TWI365882B (en) * | 2007-06-15 | 2012-06-11 | Univ Nat Chunghsing | Shigella ipab803 protein, producing method and coding nucleic acid thereof |
| CA2777837C (fr) | 2008-10-27 | 2017-07-11 | Novartis Ag | Procede de purification |
| US9040253B2 (en) | 2010-04-14 | 2015-05-26 | Sutro Biopharma, Inc. | Method for enhancing recombinant protein production by cell-free protein expression system |
| WO2013020090A2 (fr) | 2011-08-04 | 2013-02-07 | The Regents Of The University Of California | Glycopolypeptides dépourvus de glcnac streptococcique, glucides de paroi cellulaire, vaccins streptococciques et procédés pour les fabriquer et les utiliser |
| US9492523B2 (en) * | 2011-12-09 | 2016-11-15 | The Board Of Regents For Oklahoma State University | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| PL2906592T3 (pl) | 2012-10-12 | 2019-07-31 | Sutro Biopharma, Inc. | Proteolityczna inaktywacja wybranych białek w ekstraktach bakteryjnych dla ulepszonej ekspresji |
| DK3055321T3 (en) * | 2013-10-11 | 2018-12-17 | Sutro Biopharma Inc | Non-natural amino acid tRNA synthetases for para-methylazido-1-phenylalanine |
| MX2017001638A (es) * | 2014-08-05 | 2017-04-27 | Glaxosmithkline Biologicals Sa | Molecula portadora para antigenos. |
| US10716839B2 (en) | 2015-04-13 | 2020-07-21 | University Of Maryland, Baltimore | Compositions and methods for producing bacterial conjugate vaccines |
| CN110366428B (zh) * | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| WO2020010000A1 (fr) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Procédés améliorés pour la préparation de conjugués immunogènes |
| WO2020010016A1 (fr) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Conjugués immunogènes auto-adjuvés |
-
2020
- 2020-03-27 KR KR1020217035696A patent/KR20210146392A/ko not_active Ceased
- 2020-03-27 WO PCT/US2020/025384 patent/WO2020205584A1/fr not_active Ceased
- 2020-03-27 CN CN202080040388.1A patent/CN114025789A/zh active Pending
- 2020-03-27 MA MA055528A patent/MA55528A/fr unknown
- 2020-03-27 EA EA202192401A patent/EA202192401A1/ru unknown
- 2020-03-27 EP EP20721034.5A patent/EP3946443A1/fr active Pending
- 2020-03-27 PH PH1/2021/552430A patent/PH12021552430A1/en unknown
- 2020-03-27 TW TW109110651A patent/TW202102527A/zh unknown
- 2020-03-27 AU AU2020253332A patent/AU2020253332A1/en active Pending
- 2020-03-27 MX MX2021012120A patent/MX2021012120A/es unknown
- 2020-03-27 BR BR112021019826A patent/BR112021019826A2/pt unknown
- 2020-03-27 JP JP2021559041A patent/JP2022527206A/ja active Pending
- 2020-03-27 SG SG11202110803YA patent/SG11202110803YA/en unknown
- 2020-03-27 CA CA3135489A patent/CA3135489A1/fr active Pending
-
2021
- 2021-09-29 IL IL286819A patent/IL286819A/en unknown
- 2021-10-01 US US17/492,190 patent/US12280097B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12280097B2 (en) | 2025-04-22 |
| KR20210146392A (ko) | 2021-12-03 |
| US20220125907A1 (en) | 2022-04-28 |
| CN114025789A (zh) | 2022-02-08 |
| AU2020253332A1 (en) | 2021-11-25 |
| PH12021552430A1 (en) | 2022-07-11 |
| EP3946443A1 (fr) | 2022-02-09 |
| MX2021012120A (es) | 2021-11-03 |
| WO2020205584A1 (fr) | 2020-10-08 |
| SG11202110803YA (en) | 2021-10-28 |
| EA202192401A1 (ru) | 2022-03-30 |
| CA3135489A1 (fr) | 2020-10-08 |
| BR112021019826A2 (pt) | 2021-12-07 |
| JP2022527206A (ja) | 2022-05-31 |
| TW202102527A (zh) | 2021-01-16 |
| IL286819A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3962296A4 (fr) | Compositions de cannabinoïdes et procédés d'utilisation | |
| EP4037695A4 (fr) | Compositions oligonucléotidiques et leurs procédés d'utilisation | |
| EP3962497A4 (fr) | Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation | |
| EP3790596A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| EP3906039A4 (fr) | Polynucléotides d'arn encapsulés et procédés d'utilisation | |
| GB202015827D0 (en) | 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto | |
| IL287214A (en) | Adeno-associated virus vector formulations and methods | |
| IL286847A (en) | Hsp90-binding conjugates and formulations thereof | |
| EP3694886A4 (fr) | Récepteur d'antigène chimérique composé (ccar) ciblant de multiples antigènes et procédés d'utilisation associés | |
| IL290141A (en) | Formulations of anti-pvrig antibodies and uses thereof | |
| EP3911338A4 (fr) | Compositions et procédés d'inhibition d'antigènes spécifiques de lignée | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| EP3917543A4 (fr) | Compositions de nitrate améliorées et procédés d'utilisation | |
| EP3891272A4 (fr) | Compositions et procédés d'immunothérapie | |
| IL285963A (en) | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy | |
| EP3912683A4 (fr) | Composition cosmétique d'écran solaire | |
| EP3893917A4 (fr) | Compositions d'il-15 et leurs procédés d'utilisation | |
| EP4034605A4 (fr) | Compositions de polissage et leurs procédés d'utilisation | |
| EP3621660A4 (fr) | Compositions et procédés d'utilisation de capsides arc | |
| EP3768677A4 (fr) | Compositions d'activateurs de canal kv7 et procédés d'utilisation | |
| EP3803403A4 (fr) | Compositions et procédés d'imagerie | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3911355A4 (fr) | Lubricines recombinantes, compositions et procédés d'utilisation de celles-ci | |
| EP4045226A4 (fr) | Compositions de polissage et leurs procédés d'utilisation |